Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.96) per share for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.97) EPS and FY2026 earnings at ($4.12) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business’s revenue for the quarter was down 55.1% compared to the same quarter last year. During the same period last year, the company earned ($0.58) EPS.

Other research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price target (up previously from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday, June 3rd. UBS Group lowered their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Guggenheim restated a “buy” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Finally, Bank of America upgraded shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price objective for the company in a research report on Monday, June 2nd. Two investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $59.11.

Kymera Therapeutics Stock Up 2.0%

KYMR stock opened at $41.55 on Thursday. The business’s fifty day moving average is $44.74 and its 200-day moving average is $36.48. The company has a market cap of $2.97 billion, a P/E ratio of -11.97 and a beta of 2.18. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $53.27.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of KYMR. Commodore Capital LP bought a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $32,730,000. Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock valued at $164,134,000 after acquiring an additional 689,547 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of Kymera Therapeutics in the 4th quarter valued at about $23,856,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares in the last quarter.

Insider Activity

In related news, Director Bvf Partners L. P/Il acquired 317,167 shares of the firm’s stock in a transaction dated Monday, June 30th. The stock was bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the acquisition, the director directly owned 2,798,795 shares of the company’s stock, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares of the company’s stock, valued at $32,363,618. The trade was a 4.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is currently owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.